Two European biotechs are upping the ante on their collaboration.
Genmab and BioNTech will expand their relationship to develop and potentially commercialize new immunotherapies for the treatment of cancer. The companies will work jointly on research, development and then commercialization of the monospecific antibody candidates for various cancer indications.
The duo came together well before BioNTech became a household name because of its Covid-19 mRNA vaccine with Pfizer. Genmab and its German partner started the joint development of bispecific cancer antibodies in 2015.
“The expansion of our collaboration with Genmab expands our antibody portfolio and will further strengthen our oncology pipeline in indications with high unmet medical needs. We are committed to working together with our colleagues at Genmab to develop new treatments for people affected by cancer,” BioNTech CEO Uğur Şahin said in a statement.
The collaboration will see the companies jointly develop and commercialize…
Click here to view original post